Targeting Menin May Induce Responses in Patients With Acute Leukemias and KMT2A Rearrangements or NPM1 Mutations

Get Permission

Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with an oral small-molecule inhibitor of the menin-KMT2A interaction, SNDX-5613—now named revumenib—yielded encouraging responses for patients with advanced acute leukemias and KMT2A rearrangements or mutant NPM1. Findings from the phase I/II AUGMENT-101 trial were presented by Issa et al at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 63).

The overall response rate among 60 patients was 53%, and the rate of complete remission or complete remission with partial hematologic recovery was 30%, with 78% of patients achieving clearance of measurable residual disease. Responses were seen across multiple dose levels.

“Acute leukemias with KMT2A rearrangements are difficult to treat, and NPM1 mutations are the most common genetic alteration in acute myeloid leukemia. These subsets have no specifically approved targeted therapies,” said lead study author Ghayas Issa, MD, Assistant Professor of Leukemia at MD Anderson. “I am encouraged by these results, which suggest that SNDX-5613 may be an effective oral targeted therapy for patients with an acute leukemia caused by these genetic alterations. These response rates, especially rates of residual disease clearance, are the highest we have seen with any monotherapy used for these resistant leukemia subsets.”

In KMT2A-rearranged or NPM1-mutant acute leukemias, the interaction of the menin protein with KMT2A is critical in driving the expression of leukemia-promoting genes. Leukemias with KMT2A rearrangements occur in infants, children, and adults, and NPM1 mutations are the most common genetic alteration in acute myeloid leukemia. Preclinical studies suggested that targeting the interaction between menin and KMT2A may be an effective strategy for treating cancers with these mutations.

AUGMENT-101 Details

The AUGMENT-101 study is a first-in-human, open-label, dose-escalation and dose-expansion study evaluating the safety and antitumor activity of SNDX-5613 in children and adults with advanced KMT2A-rearranged or NPM1-mutant acute myeloid or lymphoid leukemias.

The trial enrolled 68 patients with a median age of 43 years, including children as young as 10 months of age. Disease types included acute myeloid leukemia (82%), acute lymphocytic leukemia (16%), and mixed-phenotype acute leukemia (2%). Among enrolled patients, 67.6% had KMT2A rearrangements, 20.6% had NPM1 mutations, and 11.8% had other genotypes. Patients were heavily pretreated—with a median of four prior lines of therapy—and 46% had undergone a prior allogeneic stem cell transplant. 


The median duration of response was 9.1 months and median overall survival was 7 months. Twelve patients proceeded to allogeneic stem cell transplant following response to SNDX-5613.

There were no treatment discontinuations due to treatment-related adverse events. Differentiation syndrome—an occurrence previously described with other targeted therapies in myeloid leukemias leading to differentiation of leukemia cells into normal hematopoietic cells—was reported in 11 patients. Manifestations of differentiation syndrome in all patients resolved with steroids and/or hydroxyurea, and all were grade 2 or lower.

The most common treatment-related adverse event was asymptomatic prolongation of the QT interval on electrocardiography, with a grade 3 rate of 13%. Other grade 3 or higher treatment-related adverse events included diarrhea (3%), fatigue (3%), anemia (3%), tumor-lysis syndrome (2%), neutropenia (2%), thrombocytopenia (2%), hypercalcemia (2%), and hypokalemia (2%).

“The responses in this trial show that menin inhibitors may be a promising treatment option that is well tolerated by patients and could be the newest addition to successful targeted therapies for acute leukemia,” Dr. Issa said. “I look forward to additional data from this and future trials to inform the potential opportunity to offer this targeted treatment to more patients.”

Data from one of the phase II cohorts is expected in 2023. Future trials of SNDX-5613 will test combinations with other agents in various settings, including newly diagnosed leukemias, relapsed or refractory disease, and maintenance therapy, for KMT2A-rearranged or NPM1-mutant leukemias and other leukemias susceptible to menin inhibition.

Disclosure: This study was supported by Syndax Pharmaceuticals; Dr. Issa serves as a consultant to Syndax Pharmaceuticals. For full disclosures of the study authors, visit

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.